Published in Blood on January 01, 2000
Interleukin-6 in aging and chronic disease: a magnificent pathway. J Gerontol A Biol Sci Med Sci (2006) 2.85
Idiopathic multicentric Castleman's disease: a systematic literature review. Lancet Haematol (2016) 2.36
The paradigm of IL-6: from basic science to medicine. Arthritis Res (2002) 2.34
IL-6 as a keystone cytokine in health and disease. Nat Immunol (2015) 2.14
Anti-interleukin 6 receptor antibody treatment in rheumatic disease. Ann Rheum Dis (2000) 1.56
gp130 at the nexus of inflammation, autoimmunity, and cancer. J Leukoc Biol (2010) 1.48
The clinical spectrum of Castleman's disease. Am J Hematol (2012) 1.41
Castleman's disease: from basic mechanisms to molecular therapeutics. Oncologist (2011) 1.40
Averting inflammation by targeting the cytokine environment. Nat Rev Drug Discov (2010) 1.36
Targeting interleukin-6: all the way to treat autoimmune and inflammatory diseases. Int J Biol Sci (2012) 1.27
Human and viral interleukin-6 and other cytokines in Kaposi sarcoma herpesvirus-associated multicentric Castleman disease. Blood (2013) 1.23
Successful treatment of a Caucasian case of multifocal Castleman's disease with TAFRO syndrome with a pathophysiology targeted therapy - a case report. Exp Hematol Oncol (2015) 1.19
Interleukin-6 aborts lymphopoiesis and elevates production of myeloid cells in systemic lupus erythematosus-prone B6.Sle1.Yaa animals. Blood (2009) 1.17
HHV-8-encoded viral IL-6 collaborates with mouse IL-6 in the development of multicentric Castleman disease in mice. Blood (2012) 1.14
Interleukin 6 and rheumatoid arthritis. Biomed Res Int (2014) 1.00
Interleukin-6 inhibitors in the treatment of rheumatoid arthritis. Ther Clin Risk Manag (2008) 1.00
Pharmacokinetics, pharmacodynamics and safety of a human anti-IL-6 monoclonal antibody (sirukumab) in healthy subjects in a first-in-human study. Br J Clin Pharmacol (2011) 0.99
The varying faces of IL-6: From cardiac protection to cardiac failure. Cytokine (2015) 0.98
Tocilizumab. MAbs (2009) 0.97
Castleman disease. Korean J Hematol (2012) 0.96
Tocilizumab: The evidence for its place in the treatment of juvenile idiopathic arthritis. Core Evid (2010) 0.96
Castleman's disease--a two compartment model of HHV8 infection. Nat Rev Clin Oncol (2010) 0.95
Abdominal obesity exhibits distinct effect on inflammatory and anti-inflammatory proteins in apparently healthy Japanese men. Cardiovasc Diabetol (2007) 0.94
Multicentric Castleman disease: Where are we now? Semin Diagn Pathol (2016) 0.94
Elevated plasma interleukin-6 levels in trained male triathletes following an acute period of intense interval training. Eur J Appl Physiol (2006) 0.94
Persistent or recurrent Castleman's disease - Look out for a lurking lymphoma! Indian J Med Paediatr Oncol (2011) 0.93
International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease. Blood (2017) 0.92
Laboratory and febrile features after joint surgery in patients with rheumatoid arthritis treated with tocilizumab. Ann Rheum Dis (2008) 0.90
An unusual presentation of Castleman's disease:a case report. BMC Infect Dis (2003) 0.90
Interleukin-6/soluble interleukin-6 receptor signaling attenuates proliferation and invasion, and induces morphological changes of a newly established pleomorphic malignant fibrous histiocytoma cell line. Am J Pathol (2004) 0.89
Tocilizumab for the treatment of rheumatoid arthritis and other systemic autoimmune diseases: current perspectives and future directions. Int J Rheumatol (2012) 0.89
Response of plasma IL-6 and its soluble receptors during submaximal exercise to fatigue in sedentary middle-aged men. Cell Stress Chaperones (2008) 0.87
Aryl hydrocarbon receptor and experimental autoimmune arthritis. Semin Immunopathol (2013) 0.86
Fatigue in systemic lupus erythematosus. Int J Clin Rheumtol (2012) 0.84
Cytokine homologs of human gammaherpesviruses. J Interferon Cytokine Res (2011) 0.83
Renal complications of Castleman's disease: report of two cases and analysis of 75 cases. Clin Exp Nephrol (2011) 0.83
A case of multicentric Castleman's disease having lung lesion successfully treated with humanized anti-interleukin-6 receptor antibody, tocilizumab. J Korean Med Sci (2010) 0.82
Sustained remission of severe Multicentric Castleman disease following multiagent chemotherapy and tocilizumab maintenance. Pediatr Blood Cancer (2013) 0.82
High circulating levels of biologically inactive IL-6/SIL-6 receptor complexes in systemic juvenile idiopathic arthritis: evidence for serum factors interfering with the binding to gp130. Clin Exp Immunol (2003) 0.82
Durable remission of HIV-negative, Kaposi's sarcoma herpes virus-associated multicentric Castleman disease in patient with rheumatoid arthritis treated with methotrexate. Clin Rheumatol (2006) 0.81
Interleukin-6: a new therapeutic target in systemic sclerosis? Clin Transl Immunology (2013) 0.81
Cases report of unicentric Castleman's disease: revisit of radiotherapy role. Radiat Oncol J (2013) 0.81
Autocrine insulin-like growth factor 1 and stem cell factor but not interleukin 6 support self-renewal of human myeloma cells. Blood Cancer J (2013) 0.80
Current and Potential Treatments for Ubiquitous but Neglected Herpesvirus Infections. Chem Rev (2014) 0.80
Castleman's disease in the retroperitoneal space mimicking a paraspinal schwannoma: a case report. World J Surg Oncol (2013) 0.78
Castleman disease in the parapharyngeal space: a case report and review of the literature. Head Neck Pathol (2013) 0.78
Influence of humanized anti-IL-6R antibody, tocilizumab on the activity of soluble gp130, natural inhibitor of IL-6 signaling. Rheumatol Int (2008) 0.77
The efficacy of tocilizumab in a patient with pulmonary arterial hypertension associated with Castleman's disease. Heart Vessels (2010) 0.77
Interleukin-6: an emerging regulator of pathological pain. J Neuroinflammation (2016) 0.76
Contribution of viral mimics of cellular genes to KSHV infection and disease. Viruses (2014) 0.76
Review of siltuximab in the treatment of multicentric Castleman's disease. Ther Adv Hematol (2016) 0.75
The effect of Zingiber officinale R. rhizomes (ginger) on plasma pro-inflammatory cytokine levels in well-trained male endurance runners. Cent Eur J Immunol (2014) 0.75
Unicentric Castleman's disease of abdomen. J Radiol Case Rep (2013) 0.75
[Interleukin-6 inhibition as a potential therapeutic target in rheumatic diseases]. Z Rheumatol (2014) 0.75
Diagnostic issues in a case of hodgkin lymphoma with castleman like features. Indian J Hematol Blood Transfus (2014) 0.75
Multicentric Castleman's disease: "A rare entity that mimics malignancy". Lung India (2016) 0.75
Intra-abdominal localized hyaline-vascular Castleman disease: imaging characteristics and management of a rare condition. Arch Med Sci (2016) 0.75
A comorbid case of multicentric Castleman's disease and pulmonary hyalinising granuloma successfully treated with tocilizumab and corticosteroid. BMJ Case Rep (2013) 0.75
Active immunization with Tocilizumab mimotopes induces specific immune responses. BMC Biotechnol (2015) 0.75
The effect of tapering period on plasma pro-inflammatory cytokine levels and performance in elite male cyclists. J Sports Sci Med (2009) 0.75
Episodic fevers and vasodilatory shock mimicking urosepsis in a patient with HIV-associated multicentric Castleman's Disease: a case report. BMC Infect Dis (2016) 0.75
A case report of retroperitoneal pararenal Castleman's disease associated with myasthenia gravis. World J Surg Oncol (2014) 0.75
Systemic juvenile idiopathic arthritis mimics multicentric Castleman's disease. Clin Rheumatol (2003) 0.75
[Castleman's disease]. Mund Kiefer Gesichtschir (2005) 0.75
Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell (1997) 18.91
Adult T-cell leukemia: antigen in an ATL cell line and detection of antibodies to the antigen in human sera. Proc Natl Acad Sci U S A (1981) 11.92
Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature (1996) 10.67
Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis. Proc Natl Acad Sci U S A (1990) 9.98
A nuclear factor for IL-6 expression (NF-IL6) is a member of a C/EBP family. EMBO J (1990) 9.17
Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature (1994) 8.85
Impaired B-lymphopoiesis, myelopoiesis, and derailed cerebellar neuron migration in CXCR4- and SDF-1-deficient mice. Proc Natl Acad Sci U S A (1998) 7.69
The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract. Nature (1998) 7.38
Gene mapping of the putative structural region of the hepatitis C virus genome by in vitro processing analysis. Proc Natl Acad Sci U S A (1991) 7.15
Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality. Proc Natl Acad Sci U S A (1997) 7.08
Essential role of Stat6 in IL-4 signalling. Nature (1996) 6.56
Molecular cloning of APRF, a novel IFN-stimulated gene factor 3 p91-related transcription factor involved in the gp130-mediated signaling pathway. Cell (1994) 6.45
The immune responses in CD40-deficient mice: impaired immunoglobulin class switching and germinal center formation. Immunity (1994) 6.18
Primary structure and expression from complementary DNA of skeletal muscle ryanodine receptor. Nature (1989) 6.07
Structure and function of a new STAT-induced STAT inhibitor. Nature (1997) 6.02
Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130. Cell (1989) 5.72
Epstein-Barr virus nuclear antigen 2 specifically induces expression of the B-cell activation antigen CD23. Proc Natl Acad Sci U S A (1987) 5.68
Fission yeast Slp1: an effector of the Mad2-dependent spindle checkpoint. Science (1998) 5.39
Gp130 and the interleukin-6 family of cytokines. Annu Rev Immunol (1997) 5.38
Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum (2006) 5.20
Biological and clinical aspects of interleukin 6. Immunol Today (1990) 5.17
Biology of multifunctional cytokines: IL 6 and related molecules (IL 1 and TNF). FASEB J (1990) 5.16
Molecular cloning and expression of an IL-6 signal transducer, gp130. Cell (1990) 5.06
Cloning and expression of the human interleukin-6 (BSF-2/IFN beta 2) receptor. Science (1988) 4.93
Stat3 activation is responsible for IL-6-dependent T cell proliferation through preventing apoptosis: generation and characterization of T cell-specific Stat3-deficient mice. J Immunol (1998) 4.74
Defective NK cell activity and Th1 response in IL-18-deficient mice. Immunity (1998) 4.70
Clinical Studies on Behçet's Syndrome. Ann Rheum Dis (1963) 4.61
Defective adipocyte differentiation in mice lacking the C/EBPbeta and/or C/EBPdelta gene. EMBO J (1997) 4.51
Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood (2000) 4.37
Targeted disruption of the NF-IL6 gene discloses its essential role in bacteria killing and tumor cytotoxicity by macrophages. Cell (1995) 4.34
The essential role of B cell stimulatory factor 2 (BSF-2/IL-6) for the terminal differentiation of B cells. J Exp Med (1988) 4.31
Molecular cloning and structure of a pre-B-cell growth-stimulating factor. Proc Natl Acad Sci U S A (1994) 4.25
Transcription factors NF-IL6 and NF-kappa B synergistically activate transcription of the inflammatory cytokines, interleukin 6 and interleukin 8. Proc Natl Acad Sci U S A (1993) 4.23
Flamingo, a seven-pass transmembrane cadherin, regulates planar cell polarity under the control of Frizzled. Cell (1999) 4.07
Interleukin-6 in biology and medicine. Adv Immunol (1993) 4.06
IgG1 plasmacytosis in interleukin 6 transgenic mice. Proc Natl Acad Sci U S A (1989) 4.03
Mice lacking the vitamin D receptor exhibit impaired bone formation, uterine hypoplasia and growth retardation after weaning. Nat Genet (1997) 3.89
Infection with HIV is associated with elevated IL-6 levels and production. J Immunol (1990) 3.89
Mitochondrial myopathies. Ann Neurol (1985) 3.81
Elucidation of the Erwinia uredovora carotenoid biosynthetic pathway by functional analysis of gene products expressed in Escherichia coli. J Bacteriol (1990) 3.78
Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson disease. Neurology (2010) 3.70
Structure and expression of human B cell stimulatory factor-2 (BSF-2/IL-6) gene. EMBO J (1987) 3.64
An electrophoretic karyotype for Schizosaccharomyces pombe by pulsed field gel electrophoresis. Nucleic Acids Res (1987) 3.59
Phosphorylation at threonine-235 by a ras-dependent mitogen-activated protein kinase cascade is essential for transcription factor NF-IL6. Proc Natl Acad Sci U S A (1993) 3.59
Cloning and expression in Escherichia coli of the gene for human tumour necrosis factor. Nature (1985) 3.59
Natural thymocytotoxic autoantibody and reactive antigen in New Zealand black and other mice. Proc Natl Acad Sci U S A (1971) 3.50
Composite motifs and repeat symmetry in S. pombe centromeres: direct analysis by integration of NotI restriction sites. Cell (1989) 3.46
Purification to homogeneity and characterization of human B-cell differentiation factor (BCDF or BSFp-2). Proc Natl Acad Sci U S A (1985) 3.46
Role of IQGAP1, a target of the small GTPases Cdc42 and Rac1, in regulation of E-cadherin- mediated cell-cell adhesion. Science (1998) 3.39
Nonadipose tissue production of leptin: leptin as a novel placenta-derived hormone in humans. Nat Med (1997) 3.35
Maturational disturbance of chondrocytes in Cbfa1-deficient mice. Dev Dyn (1999) 3.33
Critical cytoplasmic region of the interleukin 6 signal transducer gp130 is conserved in the cytokine receptor family. Proc Natl Acad Sci U S A (1991) 3.31
Interleukins and IgA synthesis. Human and murine interleukin 6 induce high rate IgA secretion in IgA-committed B cells. J Exp Med (1989) 3.28
Haematopoietic cell-specific CDM family protein DOCK2 is essential for lymphocyte migration. Nature (2001) 3.24
IL-6-induced homodimerization of gp130 and associated activation of a tyrosine kinase. Science (1993) 3.13
Hypervariable regions in the putative glycoprotein of hepatitis C virus. Biochem Biophys Res Commun (1991) 3.09
IL-6 is required for the development of Th1 cell-mediated murine colitis. J Immunol (2000) 3.08
Bacterial lipopolysaccharide and inflammatory mediators augment IL-6 secretion by human endothelial cells. J Immunol (1989) 3.01
LIFR beta and gp130 as heterodimerizing signal transducers of the tripartite CNTF receptor. Science (1993) 2.93
B cell stimulating factor 2/interleukin 6 is a costimulant for human thymocytes and T lymphocytes. J Exp Med (1988) 2.88
Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation. J Bone Miner Res (1996) 2.86
Selective reduction of V alpha 14+ NK T cells associated with disease development in autoimmune-prone mice. J Immunol (1996) 2.83
CNTF and LIF act on neuronal cells via shared signaling pathways that involve the IL-6 signal transducing receptor component gp130. Cell (1992) 2.83
IL-6 and NF-IL6 in acute-phase response and viral infection. Immunol Rev (1992) 2.80
AIDS Kaposi sarcoma-derived cells produce and respond to interleukin 6. Proc Natl Acad Sci U S A (1990) 2.79
Factors affecting B-cell growth and differentiation. Annu Rev Immunol (1985) 2.78
Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Arthritis Rheum (2002) 2.75
Targeted disruption of gp130, a common signal transducer for the interleukin 6 family of cytokines, leads to myocardial and hematological disorders. Proc Natl Acad Sci U S A (1996) 2.70
Xenopus M phase MAP kinase: isolation of its cDNA and activation by MPF. EMBO J (1991) 2.68
Rheumatoid factor secretion from human Leu-1+ B cells. Science (1987) 2.65
STAT3 activation is a critical step in gp130-mediated terminal differentiation and growth arrest of a myeloid cell line. Proc Natl Acad Sci U S A (1996) 2.64
Severely reduced production of klotho in human chronic renal failure kidney. Biochem Biophys Res Commun (2001) 2.63
Macrophage differentiation-specific expression of NF-IL6, a transcription factor for interleukin-6. Blood (1992) 2.62
Molecular cloning of hepatitis C virus genome from a single Japanese carrier: sequence variation within the same individual and among infected individuals. Virus Res (1992) 2.56
A member of the C/EBP family, NF-IL6 beta, forms a heterodimer and transcriptionally synergizes with NF-IL6. Proc Natl Acad Sci U S A (1992) 2.55
miR-145 and miR-133a function as tumour suppressors and directly regulate FSCN1 expression in bladder cancer. Br J Cancer (2010) 2.51
T cell-replacing factor- (TRF) induced IgG secretion in a human B blastoid cell line and demonstration of acceptors for TRF. J Immunol (1981) 2.46
Interleukin-6 (IL-6) functions as an in vitro autocrine growth factor in renal cell carcinomas. FEBS Lett (1989) 2.43
Effects of size and shape (aspect ratio) on the hemodynamics of saccular aneurysms: a possible index for surgical treatment of intracranial aneurysms. Neurosurgery (1999) 2.43
Establishment of an interleukin 6 (IL 6)/B cell stimulatory factor 2-dependent cell line and preparation of anti-IL 6 monoclonal antibodies. Eur J Immunol (1988) 2.41
Wild-type Gross leukemia virus and the pathogenesis of the glomerulonephritis of New Zealand mice. J Exp Med (1971) 2.41
Constitutive and interleukin-1 (IL-1)-inducible factors interact with the IL-1-responsive element in the IL-6 gene. Mol Cell Biol (1990) 2.41
Recombinant human interleukin-6 (IL-6/BSF-2/HSF) regulates the synthesis of acute phase proteins in human hepatocytes. FEBS Lett (1988) 2.39
Cbfa1 is a positive regulatory factor in chondrocyte maturation. J Biol Chem (2000) 2.38
Interleukin 6 plays a key role in the development of antigen-induced arthritis. Proc Natl Acad Sci U S A (1998) 2.37
A 13 kb resolution cosmid map of the 14 Mb fission yeast genome by nonrandom sequence-tagged site mapping. Cell (1993) 2.36
Cyclin B interaction with microtubule-associated protein 4 (MAP4) targets p34cdc2 kinase to microtubules and is a potential regulator of M-phase microtubule dynamics. J Cell Biol (1995) 2.35
Receptors for B cell stimulatory factor 2. Quantitation, specificity, distribution, and regulation of their expression. J Exp Med (1987) 2.34
Regulation of antibody response in vitro. VI. Carrier-specific helper cells for IgG and IgE antibody response. J Immunol (1973) 2.33
Early pathological changes in the parkinsonian brain demonstrated by diffusion tensor MRI. J Neurol Neurosurg Psychiatry (2004) 2.32
Accelerated apoptosis of lymphocytes by augmented induction of Bax in SSI-1 (STAT-induced STAT inhibitor-1) deficient mice. Proc Natl Acad Sci U S A (1998) 2.31